Connect with us

BioPharma

Darkpulse Inc (OTCMKTS: DPLS) Heats Up as Worldwide Leader in Distributed Fiber Sensor Solutions BOTDA Steps Up Major Media Marketing Campaign

Published

on

Darkpulse Inc (OTCMKTS: DPLS) has been on the move northbound in recent trading averaging over $2 million in dollar volume per day and making perhaps the biggest intraday move since summer of last year when the stock traded as high as $0.202. DPLS is among the top traded stocks in small caps with a huge international following of shareholders who are heavily accumulating at current levels and its easy to see why; DPLS is quickly becoming a leader in distributed fiber sensor solutions whose proprietary patented system outperforms all other distributed fiber sensors currently on the market. Darkpulse boasts a growing list of world-class capabilities and is positioning itself as the leader in infrastructure sensing and monitoring in all domains, air, land, and sea which represents an enormous market worth billions putting Darkpulse in line for serious government contracts according to many investors who are accumulating here. DPLS is already generating revenues; for the 3 months ended September 30, 2021 DPLS reported $3,500,970 in sales in their last QSB. Optilan has booked that amount in the past 2 months alone however this has not yet appeared in financial statements.  

DPLS continues to make big moves recently moving into its new National Headquarters located at 815 Walker Street, Suite 1155 Houston, TX 77002. Darkpulse now occupies approximately 4,224 sq. ft., in the Mellie Esperson Building. The Company also operates a 20,000 sq. ft., Electronics Manufacturing and R & D facility located in Tempe, Arizona. DarkPulse plans on hiring approximately 50 employees for its Houston location. DPLS also entered into a pilot project in California to monitor the structural health of bridges and roadbeds with the California Department of Transportation. CALTRANS is the first smart bridge in the world and an amazing opportunity for the Company. Darkpulse recently hired on Ross Tweedale joined Optilan as CFO; as we have reported DPLS plans to take Optilan public on the New York Stock Exchange (“NYSE”) in mid-2022 via an initial public offering (IPO) with DPLS management retaining 80% ownership of Optilan. Optilan signed major contracts in 2021 including Riyadh Water Transmission System, UK Railway, BTC Oil Pipeline, ENKA power plants, Seagreen Windfarm and a $45 million framework Contract win Recently Darkpulse formed several important partnerships with both the Everglades Foundation and Progress Humanity. The Company plans on helping craft and distribute messaging through media outlets, a documentary, a press conference and other key engagement initiatives.

Darkpulse Inc (OTCMKTS: DPLS) operating out of its new national heatquarters in Houston, Texas is a  technology company focused on the manufacture, sale, installation, and monitoring of laser sensing systems based on its patented BOTDA dark-pulse sensor technology which provides a data stream of critical metrics for assessing the health and security of infrastructure. Darkpulse technology excels when applied to live, dynamic critical infrastructure and structural monitoring, including pipeline monitoring, perimeter and structural surveillance, aircraft structural components and mining safety. The Company’s fiber-based monitoring systems can assist markets that are not currently served, and its unique technology covers extended areas and any event that is translated into the detection of a change in strain or temperature. In addition to the Company’s ongoing efforts with respect to the marketing and sales of its technology products and services to its customers, the Company also continues to explore potential strategic alliances through joint venture and licensing opportunities to further expand its global market position. DPLS recently moved into its new National Headquarters located at 815 Walker Street, Suite 1155 Houston, TX 77002. The Company now occupies approximately 4,224 sq. ft., in the Mellie Esperson Building. The Company also operates a 20,000 sq. ft., Electronics Manufacturing and R & D facility located in Tempe, Arizona. DarkPulse plans on hiring approximately 50 employees for its Houston location. To further collaboration and integration, the Company plans on relocating some of its corporate members from the United Kingdom including their Special Teams unit, which will be located in Houston. The move will enable closer teamwork to accelerate and increase value delivery through Company-wide initiatives.  DPLS is already generating revenues; for the 3 months ended September 30, 2021 DPLS reported $3,500,970 in sales. 

In this video engineers demonstrate the function of the dark-pulse based BOTDA system measuring strain on a PVC pipe. A 4″ PVC pipe specimen with 12′ length has a sensing fibre helically wrapped around it which measures the hoop strain as the pressure in the pipe is raised. Data is first collected at an internal pressure of 10 psig. The engineers then clamp one end of the pipe creating a disturbance in the strain field. This disturbance is readily seen in the second measurement demonstrating dark-pulse BOTDA system’s ability to detect sub-metre strain events. DarkPulse offers multiple configurations with increased processor capacity for faster data display including a cloud-based GUI as part of 24/7 structural health monitoring solutions. Darkpulse is a leader in distributed fiber sensor solutions. DPLS system outperforms all other distributed fiber sensors in the market today. DarkPulse’s growing list of world-class capabilities and the Company’s positioning as the leader in infrastructure sensing and monitoring in all domains, air, land, and sea which represents an enormous market worth billions puts Darkpulse in line for serious government contracts according to many investors who are buying in here. The Company continues to grow fast through acquisition. 

https://twitter.com/CarolynD8plus4/status/1500534879150346242

To Find out the inside Scoop on DPLS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DPLS

DPLS recently moved into its new National Headquarters located at 815 Walker Street, Suite 1155 Houston, TX 77002. The Company now occupies approximately 4,224 sq. ft., in the Mellie Esperson Building. The Company also operates a 20,000 sq. ft., Electronics Manufacturing and R & D facility located in Tempe, Arizona. DarkPulse plans on hiring approximately 50 employees for its Houston location. To further collaboration and integration, the Company plans on relocating some of its corporate members from the United Kingdom including their Special Teams unit, which will be located in Houston. The move will enable closer teamwork to accelerate and increase value delivery through Company-wide initiatives.

Recently Darkpulse formed several important partnerships with both the Everglades Foundation and Progress Humanity. The Company plans on helping craft and distribute messaging through media outlets, a documentary, a press conference and other key engagement initiatives. 

The Company filed a Petition against Twitter in the New York State Supreme Court, Nassau County, New York, to compel Twitter to disclose the identities of certain individuals or entities that post regularly on Twitter in an effort to battle the smear campaign that the Company believes is intended to harm its shareholders and investors, drive the price of the Company’s stock down and unlawfully profit on this conduct. This is the first of several such Petitions that will be filed against operators of social media platforms to expose the identities of these individuals so they can be properly pursued in the courts. This comes shortly after the Company filed a complaint against a convertible note debt funder for multiple alleged federal securities laws violations and is seeking the return of all stock (or its cash equivalent) amounting to $38,825,725.00 that may have been unlawfully taken by the defendant FirstFire Global Opportunity Fund, LLC. It is managements intention to take any award by the courts and issue a special dividend to all shareholders of record in DPLS (in the event cash is recovered). They also filed a complaint against EMA Financial, LLC, and its manager, Felicia Preston for multiple alleged federal securities laws violations and is seeking the return of all stock (or its cash equivalent) that may have been unlawfully taken through convertible note conversions. According to management the Company has filed 3 complaints recently against alleged securities act violators. 

Darkpulse also recently announced its intention to take its wholly-owned subsidiary, Optilan public in the U.S. in mid-2022 via an initial public offering (IPO). Management believes the move will unlock the value of Optilan for DarkPulse shareholders by creating a separate publicly traded company and will build on Optilan’s successful track record and serve to expand its markets. The Company anticipates that Optilan will apply for listing on the New York Stock Exchange (“NYSE”) directing towards public offering upon acceptance. The company plans to list 20% of Optilan shares on the NYSE while retaining 80% ownership. Optilan will remain a subsidiary of DarkPulse and the two companies will continue as strategic partners. 

In February, Ross Tweedale joined Optilan as Chief Financial Officer: Optilan is a leading independent security and communications systems integrator worldwide. With a 30-year pedigree, our customers trust us to keep the integrity of their assets safe and secure, by managing the life cycle delivery risk of our solutions. By fostering a collaborative design approach to complex problems, we provide innovative solutions, custom fit to even the most demanding of sites and scale of projects. Importantly, our commitment to our safety culture remains unwavered, to ensure that everyone goes home safely every day. Optilan orchestrates business resilience with a suite of end-to-end solutions, combined with connectivity and professional service at a global level. Today’s business environment is more dynamic than ever. In response, businesses are urged to move at “internet speed” and evolve with continuous change and disruption accepted as the new normal. The Company complements its tailored, integrated expertise with a curated ecosystem of leading manufacturers, to achieve both high quality and enduring results. 

For More on DPLS Subscribe Right Now!

DPLS has been on the move northbound in recent trading averaging over $2 million in dollar volume per day and making perhaps the biggest intraday move since summer of last year when the stock traded as high as $0.202. DPLS is among the top traded stocks in small caps with a huge international following of shareholders who are heavily accumulating at current levels and its easy to see why; DPLS is quickly becoming a leader in distributed fiber sensor solutions whose proprietary patented system outperforms all other distributed fiber sensors currently on the market. Darkpulse boasts a growing list of world-class capabilities and is positioning itself as the leader in infrastructure sensing and monitoring in all domains, air, land, and sea which represents an enormous market worth billions putting Darkpulse in line for serious government contracts according to many investors who are accumulating here. DPLS is already generating revenues; for the 3 months ended September 30, 2021 DPLS reported $3,500,970 in sales in their last QSB. Optilan has booked that amount in the past 2 months alone however this has not yet appeared in financial statements. DPLS continues to make big moves recently moving into its new National Headquarters located at 815 Walker Street, Suite 1155 Houston, TX 77002. Darkpulse now occupies approximately 4,224 sq. ft., in the Mellie Esperson Building. The Company also operates a 20,000 sq. ft., Electronics Manufacturing and R & D facility located in Tempe, Arizona. DarkPulse plans on hiring approximately 50 employees for its Houston location. DPLS also entered into a pilot project in California to monitor the structural health of bridges and roadbeds with the California Department of Transportation. CALTRANS is the first smart bridge in the world and an amazing opportunity for the Company. Darkpulse recently hired on Ross Tweedale joined Optilan as CFO; as we have reported DPLS plans to take Optilan public on the New York Stock Exchange (“NYSE”) in mid-2022 via an initial public offering (IPO) with DPLS management retaining 80% ownership of Optilan. Optilan signed major contracts in 2021 including Riyadh Water Transmission System, UK Railway, BTC Oil Pipeline, ENKA power plants, Seagreen Windfarm and a $45 million framework Contract win Recently Darkpulse formed several important partnerships with both the Everglades Foundation and Progress Humanity. The Company plans on helping craft and distribute messaging through media outlets, a documentary, a press conference and other key engagement initiatives. Microcapdaily first reported on DPLS when the stock was less than $0.01 in January. We will be updating on DPLS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with DPLS.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in DPLS either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

BioPharma

Vaccitech (NASDAQ: VACC) Gains Unprecedented Support—What’s Behind It?

Published

on

On September 25, 2023, Vaccitech (NASDAQ: VACC) experienced a jaw-dropping 90% surge in its stock price in just one day of trading. Now, this kind of jump usually happens when a company drops a major announcement or puts out a significant SEC filing. But, surprise, surprise—there was nothing of that sort this time .So naturally we did some digging, explored further online and guess what? Turns out retail traders were also not on a main reason for this rollercoaster ride. Curious to uncover what’s really behind this financial rollercoaster? Before we go any further, let’s get to know Vaccitech a bit better. There’s some pretty important aspects on the company you might like.

 

Background:

Vaccitech operates as a clinical-stage biopharmaceutical company, dedicated to discovering and developing innovative T cell immunotherapies. These therapies are crafted to leverage the immune system’s potency for treating conditions like chronic infectious diseases, cancer, and autoimmune disorders.

What sets Vaccitech apart is their distinctive, multi-platform approach, demonstrating the capacity to generate higher quantities of T cells compared to alternative technologies. This places Vaccitech in a unique position to cater to the needs of substantial, yet underserved patient populations. Their diverse clinical-stage pipeline includes potential treatments for severe diseases with limited available treatments, presenting significant public health risks.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Among their lead product candidates are VTP-300, an immunotherapeutic designed to contribute to a potential functional cure for chronic hepatitis B viral (HBV) infection. Additionally, VTP-200 is a non-invasive, early-stage investigational treatment targeting persistent, high-risk human papillomavirus (HPV). VTP-850 stands out as a novel T cell investigational therapy aimed at prostate cancer, while VTP-1000, a preclinical T cell therapeutic candidate, focuses on reinstating immune tolerance in celiac disease.

Vaccitech possesses well-established expertise in drug development and scientific knowledge within the immunization realm. Notably, they co-developed a COVID-19 vaccine in collaboration with the University of Oxford. As many of you know, their vaccine has been successfully approved and holds an exclusive license worldwide with AstraZeneca.

What happened:

The one and only thing that happened today was Alliance Global Partners adding coverage of Vaccitech with a favourable buy recommendation.What’s truly eye-catching are the projections made, suggesting some pretty significant upside. The average one-year price target for Vaccitech is $12.24. Forecasts within this period have a bit of a spectrum, reaching from a low estimate of $7.07 to a high of $15.75. With that said, from today’s closing price that’s nearly 400% gain.

What’s The Big Deal?:

Alliance Global Partners giving the green light to cover Vaccitech is like a thumbs-up from a respected expert. It’s like a top-tier food critic saying, “This restaurant is a must-try.”

Think of it as Vaccitech stepping into the spotlight. It’s like a talented musician getting featured on a famous music blog—suddenly, more people start paying attention.

When a big player like Alliance Global Partners says, “Hey, this stock is a good buy,” it’s like a friend recommending a must-watch movie. You’re more likely to check it out based on that suggestion.

This kind of recommendation can also affect the stock price. It’s similar to when a popular influencer talks about a cool product—lots of people want to try it.

In a nutshell, this coverage is like a stamp of approval, making Vaccitech catch the attention of more potential investors and possibly giving the stock a boost. But it’s important to mention that just because a well established financial firm gives a price target, does not mean it’s accurate. In fact, tons of these projections are made daily with many being totally off the mark. Always do your own due diligence.

We will update you on VACC when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by spencerbdavis1 from Pixabay

 

 

 

Continue Reading

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.